Skip to main content

Dexcom Value Stock - Dividend - Research Selection

Dexcom

ISIN: US2521311074 , WKN: A0D9T1

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Here's How Much You'd Have If You Invested $1000 in DexCom a Decade Ago

2026-08-13
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches?

2026-08-12
DexCom's broader CGM coverage, G7 15 Day rollout and rising margins support growth, but premium valuation, competition and litigation temper upside.

DXCM Stock Up Nearly 35% YTD: Will the Uptrend Continue in the Rest of 2026?

2026-08-12
DXCM's 2026 rebound is backed by stronger growth, G7 15 Day adoption and broader CGM access, but competition and reimbursement remain key risks.

DXCM Rallies 52.5% in 3 Months. Can the Stock Keep Climbing From Here?

2026-08-12
DexCom's 52.5% three-month rally is backed by earnings growth and margin gains, but premium valuation, competition and litigation raise the bar.

Can DexCom's Raised 2026 Outlook Sustain Stronger Margin Momentum?

2026-08-12
DexCom raises its 2026 revenue and margin outlook as G7 15 Day efficiencies lift profitability, while FX and transition costs remain key tests.

Tracking Baillie Gifford's 13F Portfolio - Q2 2026 Update

2026-08-06
Baillie Gifford Q2 2026 13F: portfolio grew to $110B; SpaceX IPO (SPCX) tops holdings, NVDA added, AMZN trimmed. Read more analysis here.

Wednesday's session: top gainers and losers in the S&P500 index

2026-08-05
Curious about the S&P500 stocks that are in motion on Wednesday? Join us as we explore the top movers within the S&P500 index during today's session.

DexCom (NASDAQ:DXCM) Stands Out as an Affordable Growth Stock

2026-08-04
DexCom earns a 7/10 fundamental rating, blending strong growth, reasonable valuation, and solid profitability as an affordable growth pick.

Argus Research Maintains Buy on DexCom, Raises Price Target to $96

2026-08-04
Argus Research analyst Steve Silver maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $86 to $96.

DexCom (DXCM) Q2 2026 Earnings Call Transcript

2026-08-04
Revenue hit $1.31 billion with strong international growth and margin expansion.